JPMorgan’s Foley Sees Strong IPO Growth in HK, China

JPMorgan's Kevin Foley said global deal-making remains strong despite higher rates and inflation, and expects IPO activity to rise significantly in Hong Kong and mainland China. He highlighted AI and healthcare as the key sectors likely to drive issuance. The comments are supportive for Asia ECM sentiment but are directional rather than event-driven.

Analysis

The key second-order implication is that capital formation is rotating toward sectors with higher regulatory visibility and lower upfront capex intensity. If that shift sustains, the real winners are not just the banks underwriting the deals, but the exchange ecosystem, pre-IPO shareholders looking to monetize, and domestic institutions that need paper to absorb incremental supply; the hidden loser is likely late-stage private capital, which faces tighter exit windows and weaker negotiating leverage on valuation terms.

For JPM, the near-term read-through is modestly constructive rather than explosive: underwriting and advisory pipelines should stay resilient even if M&A remains rate-constrained, because IPO activity can offset softer leverage-driven fees. The bigger margin opportunity is in Asia franchise share: if U.S. and European banks stay cautious on China risk, JPM can capture a disproportionate slice of the mandates, but that also raises concentration risk if policy sentiment or cross-border scrutiny turns.

Consensus may be underestimating how quickly this can reverse if equity market volatility rises or if one or two marquee listings price poorly. IPO windows in Hong Kong and mainland China tend to shut fast when aftermarket performance deteriorates, so the relevant horizon is weeks to months, not years. Higher rates are not the direct killer here; the killer is a broken distribution market, where investors demand bigger discounts and issuers delay launches, reducing fee momentum abruptly.

A contrarian takeaway is that enthusiasm for AI and healthcare listings may be overconcentrated in a narrow set of names while the broader funnel remains selective. That creates a barbell: a few oversubscribed deals and a long tail of delayed or down-sized offerings. If that pattern develops, the headline IPO recovery will look strong, but the economics for underwriters and sponsors may be less impressive than the top-line volume suggests.

Key Decisions for Investors

• Modestly long JPM vs. BAC/GS on a 1-3 month horizon: JPM has a cleaner Asia/China capital-markets exposure and should capture outsized share if Hong Kong IPO issuance re-accelerates; risk is that China sentiment fades and fee leverage disappoints.
• Buy JPM Jan-2026 call spreads to express a slow-burn fee recovery with limited downside: upside is renewed IPO + ECM momentum, while premium outlay is capped if rate volatility keeps a lid on deal flow.
• Pair trade: long HKEX / short a regional less-exposed exchange proxy if listed-market issuance in Hong Kong improves over the next 1-2 quarters; the trade benefits from a broader primary-market rebound without needing a full risk-on cycle.
• Avoid chasing AI/healthcare-linked China IPO proxies after the first wave of deals; instead wait for 1-2 months of post-listing performance confirmation before adding exposure, since weak aftermarket prints can shut the window quickly.
• If the next marquee Hong Kong listing prices aggressively, fade the move in listed China-related brokers on a 2-4 week horizon; consensus may be extrapolating a durable issuance reopening from a single liquid transaction.